New Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED)
DUBLIN--(BUSINESS WIRE)--Horizon announced topline data adding to the growing body of evidence supporting the efficacy and safety of TEPEZZA for Thyroid Eye Disease (TED).